{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,9,10]],"date-time":"2026-09-10T09:10:35Z","timestamp":1789031435384,"version":"build-2803163510"},"reference-count":137,"publisher":"Frontiers Media SA","license":[{"start":{"date-parts":[[2026,9,10]],"date-time":"2026-09-10T00:00:00Z","timestamp":1788998400000},"content-version":"vor","delay-in-days":0,"URL":"https:\/\/creativecommons.org\/licenses\/by\/4.0\/"}],"content-domain":{"domain":["frontiersin.org"],"crossmark-restriction":true},"short-container-title":["Front. Pharmacol."],"abstract":"<jats:p>Complement-mediated diseases are individually rare, often rapidly progressive, and historically associated with high rates of permanent organ injury or death but are now among the most therapeutically actionable conditions in pediatric nephrology, hematology, and rheumatology. As demonstrated by thrombotic microangiopathy, and hemolytic uremic syndrome in particular, diagnostic delay can contribute directly to irreversible kidney injury. Complement inhibition has substantially improved outcomes in these conditions that previously carried a substantial risk of end-stage kidney disease. This review addresses the complement system as a clinical and therapeutic framework for the practicing pediatric clinician. The pathophysiology of the major complement-mediated diseases affecting children is examined, with atypical hemolytic uremic syndrome and transplant-associated thrombotic microangiopathy as central disease models alongside paroxysmal nocturnal hemoglobinuria, C3 glomerulopathy, IgA nephropathy, and ANCA-associated vasculitis. Approved complement inhibitors are reviewed by mechanistic position in the cascade, with attention to the clinical implications of terminal versus proximal pathway inhibition. Laboratory diagnosis, monitoring, and assessment of complement blockade adequacy are addressed, including practical limitations of complement testing in clinical practice. Critical gaps are examined, including diagnostic delays, absent validated biomarkers, inadequate pediatric trial infrastructure, and conditions without targeted therapies. Emerging therapeutics, point-of-care diagnostics, and pediatric-specific considerations including transition of care and reproductive counseling complete the review. Complement therapeutics have meaningfully altered the trajectory of some of the most severe and inadequately treated pediatric diseases. This field continues to evolve rapidly, with expanding indications and novel agents, though drug development challenges, diagnostic and monitoring gaps, and equitable consideration of pediatric application of these novel agents remain essential priorities.<\/jats:p>","DOI":"10.3389\/fphar.2026.1891349","type":"journal-article","created":{"date-parts":[[2026,9,10]],"date-time":"2026-09-10T08:50:07Z","timestamp":1789030207000},"update-policy":"https:\/\/doi.org\/10.3389\/crossmark-policy","source":"Crossref","is-referenced-by-count":0,"title":["Complement diagnostics and therapeutics for the pediatric population: early successes and opportunities for further advancement"],"prefix":"10.3389","volume":"17","author":[{"given":"Russell S.","family":"Whelan","sequence":"first","affiliation":[{"name":"Renal Section, Department of Pediatrics, University of Colorado School of Medicine","place":["Aurora, CO, United States"]},{"name":"Department of Nephrology, Children\u2019s Hospital Colorado","place":["Aurora, CO, United States"]}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Bradley P.","family":"Dixon","sequence":"additional","affiliation":[{"name":"Renal Section, Department of Pediatrics, University of Colorado School of Medicine","place":["Aurora, CO, United States"]},{"name":"Department of Nephrology, Children\u2019s Hospital Colorado","place":["Aurora, CO, United States"]}],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"1965","published-online":{"date-parts":[[2026,9,10]]},"reference":[{"key":"B1","doi-asserted-by":"publisher","first-page":"104","DOI":"10.1053\/j.ackd.2019.12.003","article-title":"C3 glomerulopathy: pathogenesis and treatment","volume":"27","author":"Ahmad","year":"2020","journal-title":"Adv. Chronic Kidney Dis."},{"key":"B2","doi-asserted-by":"publisher","first-page":"101185","DOI":"10.1016\/j.xkme.2025.101185","article-title":"Crovalimab rescue therapy in a case with genetic complement mediated thrombotic microangiopathy","volume":"8","author":"Aigner","year":"2026","journal-title":"Kidney Med."},{"key":"B3","doi-asserted-by":"publisher","first-page":"2767","DOI":"10.1007\/s00467-026-07268-9","article-title":"A pediatric case of C3 glomerulonephritis initially misclassified as IgA nephropathy with a favorable response to C3-targeted therapy","volume":"41","author":"Alconcher","year":"2026","journal-title":"Pediatr. Nephrol."},{"key":"B4","doi-asserted-by":"publisher","first-page":"130","DOI":"10.17712\/nsj.2023.2.20220119","article-title":"Inherited CD59 deficiency, where neurology and genetics intertwine","volume":"28","author":"Almutawea","year":"2023","journal-title":"Neurosci. (Riyadh)"},{"key":"B5","doi-asserted-by":"publisher","first-page":"1130","DOI":"10.1093\/rheumatology\/ket488","article-title":"A comparison of the outcome of adolescent and adult-onset systemic lupus erythematosus","volume":"53","author":"Amaral","year":"2014","journal-title":"Rheumatol. Oxf."},{"key":"B6","doi-asserted-by":"publisher","first-page":"1387","DOI":"10.1007\/s00467-023-06120-8","article-title":"Complement inhibitors in pediatric kidney diseases: new therapeutic opportunities","volume":"39","author":"Antonucci","year":"2024","journal-title":"Pediatr. Nephrol."},{"key":"B7","doi-asserted-by":"publisher","first-page":"225","DOI":"10.1016\/j.kint.2020.10.046","article-title":"The long-acting C5 inhibitor, Ravulizumab, is effective and safe in pediatric patients with atypical hemolytic uremic syndrome naive to complement inhibitor treatment","volume":"100","author":"Ariceta","year":"2021","journal-title":"Kidney Int."},{"key":"B8","doi-asserted-by":"publisher","first-page":"553","DOI":"10.1080\/08916930902785363","article-title":"Intravenous immunoglobulin therapy for autoimmune diseases","volume":"42","author":"Arnson","year":"2009","journal-title":"Autoimmunity."},{"key":"B9","doi-asserted-by":"publisher","first-page":"3066","DOI":"10.1681\/ASN.2017010031","article-title":"The phenotypic spectrum of nephropathies associated with mutations in diacylglycerol kinase epsilon","volume":"28","author":"Azukaitis","year":"2017","journal-title":"J. Am. Soc. Nephrol."},{"key":"B10","doi-asserted-by":"publisher","first-page":"365","DOI":"10.1007\/s40262-020-00940-9","article-title":"Pharmacokinetic and pharmacodynamic properties of cemdisiran, an RNAi therapeutic targeting complement component 5, in healthy subjects and patients with paroxysmal nocturnal hemoglobinuria","volume":"60","author":"Badri","year":"2021","journal-title":"Clin. Pharmacokinet."},{"key":"B11","doi-asserted-by":"publisher","first-page":"465","DOI":"10.1056\/NEJMoa2600743","article-title":"Iptacopan in IgA nephropathy - final 24-Month data","volume":"395","author":"Barratt","year":"2026","journal-title":"N. Engl. J. Med."},{"key":"B12","doi-asserted-by":"publisher","first-page":"487","DOI":"10.1681\/ASN.0000000526","article-title":"Safety and efficacy of avacopan in patients with complement 3 glomerulopathy: randomized, double-blind clinical trial","volume":"36","author":"Bomback","year":"2025","journal-title":"J. Am. Soc. Nephrol."},{"key":"B13","doi-asserted-by":"publisher","first-page":"104134","DOI":"10.1016\/j.drudis.2024.104134","article-title":"The efficacy and safety of eculizumab in patients and the role of C5 polymorphisms","volume":"29","author":"Bouwman","year":"2024","journal-title":"Drug Discov. Today"},{"key":"B14","doi-asserted-by":"publisher","first-page":"1260","DOI":"10.1016\/j.kint.2020.01.045","article-title":"Long-term outcomes and response to treatment in diacylglycerol kinase epsilon nephropathy","volume":"97","author":"Brocklebank","year":"2020","journal-title":"Kidney Int."},{"key":"B15","doi-asserted-by":"publisher","first-page":"1690","DOI":"10.1021\/acs.jmedchem.3c02165","article-title":"A drug discovery perspective on FDA expedited development and incentive programs","volume":"67","author":"Brown","year":"2024","journal-title":"J. Med. Chem."},{"key":"B16","doi-asserted-by":"publisher","first-page":"101392","DOI":"10.1016\/j.lanepe.2025.101392","article-title":"Eculizumab withdrawal and monitoring in atypical haemolytic uraemic syndrome (SETS aHUS): a multicentre, open label, prospective, single arm trial","volume":"56","author":"Bryant","year":"2025","journal-title":"Lancet Reg. Health Eur."},{"key":"B17","doi-asserted-by":"publisher","first-page":"1245","DOI":"10.1681\/ASN.2015040385","article-title":"High-throughput genetic testing for thrombotic microangiopathies and C3 glomerulopathies","volume":"27","author":"Bu","year":"2016","journal-title":"J. Am. Soc. Nephrol."},{"key":"B18","doi-asserted-by":"publisher","first-page":"829","DOI":"10.1681\/ASN.2019080851","article-title":"Anti-factor B antibodies and acute postinfectious GN in children","volume":"31","author":"Chauvet","year":"2020","journal-title":"J. Am. Soc. Nephrol."},{"key":"B19","doi-asserted-by":"publisher","first-page":"102979","DOI":"10.1016\/j.jaut.2022.102979","article-title":"The complement system and human autoimmune diseases","volume":"137","author":"Coss","year":"2023","journal-title":"J. Autoimmun."},{"key":"B20","doi-asserted-by":"publisher","first-page":"e0269749","DOI":"10.1371\/journal.pone.0269749","article-title":"Pharmacokinetics and pharmacodynamics of pozelimab alone or in combination with cemdisiran in non-human primates","volume":"17","author":"Devalaraja-Narashimha","year":"2022","journal-title":"PLoS One"},{"key":"B21","doi-asserted-by":"publisher","first-page":"1081","DOI":"10.1111\/jcpt.13642","article-title":"Ravulizumab 100 mg\/mL formulation reduces infusion time and frequency, improving the patient and caregiver experience in the treatment of atypical haemolytic uraemic syndrome","volume":"47","author":"Dixon","year":"2022","journal-title":"J. Clin. Pharm. Ther."},{"key":"B22","doi-asserted-by":"publisher","first-page":"2284","DOI":"10.1016\/j.ekir.2023.08.033","article-title":"Clinical safety and efficacy of pegcetacoplan in a phase 2 study of patients with C3 glomerulopathy and other complement-mediated glomerular diseases","volume":"8","author":"Dixon","year":"2023","journal-title":"Kidney Int. Rep."},{"key":"B23","doi-asserted-by":"publisher","first-page":"1566","DOI":"10.3390\/ijms25031566","article-title":"The lectin pathway of the complement system-activation, regulation, disease connections and interplay with other (proteolytic) systems","volume":"25","author":"Dobo","year":"2024","journal-title":"Int. J. Mol. Sci."},{"key":"B24","doi-asserted-by":"publisher","first-page":"402","DOI":"10.1111\/imr.13149","article-title":"Gene targeting as a therapeutic avenue in diseases mediated by the complement alternative pathway","volume":"313","author":"Dreismann","year":"2023","journal-title":"Immunol. Rev."},{"key":"B25","doi-asserted-by":"publisher","first-page":"102686","DOI":"10.1016\/j.coi.2025.102686","article-title":"Complement-targeting therapies in hemolytic diseases","volume":"98","author":"Duval","year":"2026","journal-title":"Curr. Opin. Immunol."},{"key":"B26","doi-asserted-by":"publisher","first-page":"2237","DOI":"10.3389\/fimmu.2018.02237","article-title":"Interpretation of serological complement biomarkers in disease","volume":"9","author":"Ekdahl","year":"2018","journal-title":"Front. Immunol."},{"key":"B27","doi-asserted-by":"publisher","first-page":"40","DOI":"10.1053\/j.ajkd.2013.07.011","article-title":"Insights from the use in clinical practice of Eculizumab in adult patients with atypical hemolytic uremic syndrome affecting the native kidneys: an analysis of 19 cases","volume":"63","author":"Fakhouri","year":"2014","journal-title":"Am. J. Kidney Dis."},{"key":"B28","doi-asserted-by":"publisher","first-page":"2210","DOI":"10.1056\/NEJMoa2501510","article-title":"Trial of pegcetacoplan in C3 glomerulopathy and immune-complex MPGN","volume":"393","author":"Fakhouri","year":"2025","journal-title":"N. Engl. J. Med."},{"key":"B29","doi-asserted-by":"publisher","first-page":"1","DOI":"10.1016\/bs.acc.2016.06.001","article-title":"Overview of laboratory testing and clinical presentations of complement deficiencies and dysregulation","volume":"77","author":"Frazer-Abel","year":"2016","journal-title":"Adv. Clin. Chem."},{"key":"B30","doi-asserted-by":"publisher","first-page":"364","DOI":"10.2215\/CJN.05830518","article-title":"Complement gene variants and Shiga toxin-producing Escherichia coli-associated hemolytic uremic syndrome: retrospective genetic and clinical study","volume":"14","author":"Fremeaux-Bacchi","year":"2019","journal-title":"Clin. J. Am. Soc. Nephrol."},{"key":"B31","doi-asserted-by":"publisher","first-page":"1119","DOI":"10.1007\/s11095-025-03882-8","article-title":"First-in-class clinically investigated oral factor D inhibitors for the treatment of complement-mediated diseases","volume":"42","author":"Gadhachanda","year":"2025","journal-title":"Pharm. Res."},{"key":"B32","doi-asserted-by":"publisher","first-page":"56","DOI":"10.1053\/j.ajkd.2018.11.012","article-title":"An ex vivo test of complement activation on endothelium for individualized eculizumab therapy in hemolytic uremic syndrome","volume":"74","author":"Galbusera","year":"2019","journal-title":"Am. J. Kidney Dis."},{"key":"B33","doi-asserted-by":"publisher","first-page":"1561","DOI":"10.1681\/ASN.0000000000000182","article-title":"Efficacy and safety of Eculizumab in pediatric patients affected by Shiga toxin-related hemolytic and uremic syndrome: a randomized, placebo-controlled trial","volume":"34","author":"Garnier","year":"2023","journal-title":"J. Am. Soc. Nephrol."},{"key":"B34","doi-asserted-by":"publisher","first-page":"792","DOI":"10.1124\/pharmrev.120.000072","article-title":"Therapeutic targeting of the complement system: from rare diseases to pandemics","volume":"73","author":"Garred","year":"2021","journal-title":"Pharmacol. Rev."},{"key":"B35","doi-asserted-by":"publisher","first-page":"1112257","DOI":"10.3389\/fimmu.2023.1112257","article-title":"An ex vivo test to investigate genetic factors conferring susceptibility to atypical haemolytic uremic syndrome","volume":"14","author":"Gastoldi","year":"2023","journal-title":"Front. Immunol."},{"key":"B36","doi-asserted-by":"publisher","first-page":"2152","DOI":"10.1172\/JCI136094","article-title":"Complementopathies and precision medicine","volume":"130","author":"Gavriilaki","year":"2020","journal-title":"J. Clin. Invest"},{"key":"B37","doi-asserted-by":"publisher","first-page":"3637","DOI":"10.1182\/blood-2015-02-629683","article-title":"Modified ham test for atypical hemolytic uremic syndrome","volume":"125","author":"Gavriilaki","year":"2015","journal-title":"Blood"},{"key":"B38","doi-asserted-by":"publisher","first-page":"3571","DOI":"10.1182\/blood.2021012860","article-title":"Advancing therapeutic complement inhibition in hematologic diseases: PNH and beyond","volume":"139","author":"Gavriilaki","year":"2022","journal-title":"Blood"},{"key":"B39","doi-asserted-by":"publisher","first-page":"2751","DOI":"10.1016\/j.ekir.2025.05.041","article-title":"Treatment with avacopan in ANCA-associated vasculitis with kidney involvement","volume":"10","author":"Geetha","year":"2025","journal-title":"Kidney Int. Rep."},{"key":"B40","doi-asserted-by":"publisher","first-page":"1027","DOI":"10.1016\/j.ekir.2022.02.002","article-title":"Comparison of complement pathway activation in autoimmune glomerulonephritis","volume":"7","author":"Genest","year":"2022","journal-title":"Kidney Int. Rep."},{"key":"B41","doi-asserted-by":"publisher","first-page":"4072","DOI":"10.1182\/blood-2024-205866","article-title":"Monotherapy treatment with Zaltenibart (OMS906), an alternative pathway Masp-3 inhibitor, improved key hematologic parameters in patients with PNH with a suboptimal response to ravulizumab: interim results from a phase 2 proof-of-concept study","volume":"144","author":"Griffin","year":"2024","journal-title":"Blood"},{"key":"B42","doi-asserted-by":"publisher","first-page":"193","DOI":"10.1007\/s40272-022-00555-6","article-title":"Pharmacological management of atypical hemolytic uremic syndrome in pediatric patients: current and future","volume":"25","author":"Gurevich","year":"2023","journal-title":"Paediatr. Drugs"},{"key":"B43","doi-asserted-by":"publisher","first-page":"e70001","DOI":"10.1111\/nep.70001","article-title":"Pegcetacoplan for the treatment of paediatric C3 glomerulonephritis: a case report","volume":"30","author":"Guzman","year":"2025","journal-title":"Nephrol. Carlt."},{"key":"B44","doi-asserted-by":"publisher","first-page":"1074","DOI":"10.1111\/j.1582-4934.2008.00350.x","article-title":"The alternative complement pathway revisited","volume":"12","author":"Harboe","year":"2008","journal-title":"J. Cell Mol. Med."},{"key":"B45","doi-asserted-by":"publisher","first-page":"513","DOI":"10.1016\/j.it.2012.06.001","article-title":"The complotype: dictating risk for inflammation and infection","volume":"33","author":"Harris","year":"2012","journal-title":"Trends Immunol."},{"key":"B46","doi-asserted-by":"publisher","first-page":"464","DOI":"10.1016\/j.ekir.2023.11.025","article-title":"Defining nephritic factors as diverse drivers of systemic complement dysregulation in C3 glomerulopathy","volume":"9","author":"Hauer","year":"2024","journal-title":"Kidney Int. Rep."},{"key":"B47","doi-asserted-by":"publisher","first-page":"17028","DOI":"10.1038\/nrdp.2017.28","article-title":"Paroxysmal nocturnal haemoglobinuria","volume":"3","author":"Hill","year":"2017","journal-title":"Nat. Rev. Dis. Prim."},{"key":"B48","doi-asserted-by":"publisher","first-page":"1028","DOI":"10.1056\/NEJMoa2029073","article-title":"Pegcetacoplan versus Eculizumab in paroxysmal nocturnal hemoglobinuria","volume":"384","author":"Hillmen","year":"2021","journal-title":"N. Engl. J. Med."},{"key":"B49","doi-asserted-by":"publisher","first-page":"3067","DOI":"10.1182\/bloodadvances.2025019253","article-title":"Ravulizumab for treatment of paroxysmal nocturnal hemoglobinuria during pregnancy","volume":"10","author":"Hochsmann","year":"2026","journal-title":"Blood Adv."},{"key":"B50","doi-asserted-by":"publisher","first-page":"2289","DOI":"10.1007\/s00467-018-4034-z","article-title":"Outcome of membranoproliferative glomerulonephritis and C3-glomerulopathy in children and adolescents","volume":"33","author":"Holle","year":"2018","journal-title":"Pediatr. Nephrol."},{"key":"B51","doi-asserted-by":"publisher","first-page":"113","DOI":"10.1111\/nyas.13522","article-title":"Myasthenia gravis: the role of complement at the neuromuscular junction","volume":"1412","author":"Howard","year":"2018","journal-title":"Ann. N. Y. Acad. Sci."},{"key":"B52","doi-asserted-by":"publisher","first-page":"976","DOI":"10.1016\/S1474-4422(17)30369-1","article-title":"Safety and efficacy of Eculizumab in anti-acetylcholine receptor antibody-positive refractory generalised myasthenia gravis (REGAIN): a phase 3, randomised, double-blind, placebo-controlled, multicentre study","volume":"16","author":"Howard","year":"2017","journal-title":"Lancet Neurol."},{"key":"B53","doi-asserted-by":"publisher","first-page":"582","DOI":"10.1001\/jamaneurol.2019.5125","article-title":"Clinical effects of the self-administered subcutaneous complement inhibitor zilucoplan in patients with moderate to severe generalized myasthenia gravis: results of a phase 2 randomized, double-blind, placebo-controlled, multicenter clinical trial","volume":"77","author":"Howard","year":"2020","journal-title":"JAMA Neurol."},{"key":"B54","doi-asserted-by":"publisher","first-page":"565","DOI":"10.1007\/s00428-020-02800-0","article-title":"Complement activation is associated with crescent formation in IgA nephropathy","volume":"477","author":"Itami","year":"2020","journal-title":"Virchows Arch."},{"key":"B55","first-page":"1","volume-title":"Efficacy and Safety of Eculizumab in Children with Shiga-Toxin-Producing Efficacy Mech. Eval.","author":"Ives","year":"2024"},{"key":"B56","doi-asserted-by":"publisher","DOI":"10.2215\/CJN.0000001020","article-title":"Practical considerations for infection prevention with the clinical use of complement inhibitors","author":"Java","year":"2026","journal-title":"Clin. J. Am. Soc. Nephrol."},{"key":"B57","doi-asserted-by":"publisher","first-page":"599","DOI":"10.1056\/NEJMoa2023386","article-title":"Avacopan for the treatment of ANCA-associated vasculitis","volume":"384","author":"Jayne","year":"2021","journal-title":"N. Engl. J. Med."},{"key":"B58","doi-asserted-by":"publisher","first-page":"e70181","DOI":"10.1111\/nep.70181","article-title":"Clinical characteristics of 30 cases of childhood haemolytic uremic syndrome in a single centre","volume":"31","author":"Jiang","year":"2026","journal-title":"Nephrol. Carlt."},{"key":"B138","doi-asserted-by":"publisher","first-page":"1049","DOI":"10.1182\/blood.2019004218","article-title":"Complement blockade for TA-TMA: lessons learned from a large pediatric cohort treated with eculizumab","volume":"135","author":"Jodele","year":"2020","journal-title":"Blood"},{"key":"B59","doi-asserted-by":"publisher","first-page":"1112","DOI":"10.1182\/blood.2023022526","article-title":"A prospective multi-institutional study of Eculizumab to treat high-risk stem cell transplantation-associated TMA","volume":"143","author":"Jodele","year":"2024","journal-title":"Blood"},{"key":"B60","doi-asserted-by":"publisher","first-page":"831044","DOI":"10.3389\/fimmu.2021.831044","article-title":"Editorial: function and dysfunction of complement factor H","volume":"12","author":"Jozsi","year":"2021","journal-title":"Front. Immunol."},{"key":"B61","doi-asserted-by":"publisher","first-page":"101331","DOI":"10.1016\/j.smim.2019.101331","article-title":"Complement dysregulation in glomerulonephritis","volume":"45","author":"Kaartinen","year":"2019","journal-title":"Semin. Immunol."},{"key":"B62","doi-asserted-by":"publisher","first-page":"gfaf116.0342","DOI":"10.1093\/ndt\/gfaf116.0342","article-title":"#3060 A phase 3, open-label, multicenter study of ravulizumab in pediatric patients with IgA nephropathy or IgA vasculitis-associated nephritis","volume":"40","author":"Kateifides","year":"2025","journal-title":"Nephrol. Dial. Transplant."},{"key":"B63","doi-asserted-by":"publisher","first-page":"1587","DOI":"10.1016\/S0140-6736(25)01148-1","article-title":"Oral iptacopan therapy in patients with C3 glomerulopathy: a randomised, double-blind, parallel group, multicentre, placebo-controlled, phase 3 study","volume":"406","author":"Kavanagh","year":"2025","journal-title":"Lancet"},{"key":"B64","doi-asserted-by":"publisher","first-page":"1032","DOI":"10.1056\/NEJMoa1502950","article-title":"Eculizumab in pregnant patients with paroxysmal nocturnal hemoglobinuria","volume":"373","author":"Kelly","year":"2015","journal-title":"N. Engl. J. Med."},{"key":"B65","doi-asserted-by":"publisher","first-page":"420","DOI":"10.1002\/art.40747","article-title":"Association of blood concentrations of complement split product iC3b and serum C3 with systemic lupus erythematosus disease activity","volume":"71","author":"Kim","year":"2019","journal-title":"Arthritis Rheumatol."},{"key":"B66","doi-asserted-by":"publisher","first-page":"870","DOI":"10.1016\/j.ejpn.2018.04.003","article-title":"CD59 deficiency presenting as polyneuropathy and moyamoya syndrome with endothelial abnormalities of small brain vessels","volume":"22","author":"Klemann","year":"2018","journal-title":"Eur. J. Paediatr. Neurol."},{"key":"B67","doi-asserted-by":"publisher","first-page":"358","DOI":"10.1111\/imr.13138","article-title":"With complements: C3 inhibition in the clinic","volume":"313","author":"Kolev","year":"2023","journal-title":"Immunol. Rev."},{"key":"B68","doi-asserted-by":"publisher","first-page":"645","DOI":"10.1681\/ASN.0000000534","article-title":"Efficacy and safety of Ravulizumab in IgA nephropathy: a phase 2 randomized double-blind placebo-controlled trial","volume":"36","author":"Lafayette","year":"2025","journal-title":"J. Am. Soc. Nephrol."},{"key":"B69","doi-asserted-by":"publisher","first-page":"629","DOI":"10.1016\/j.tips.2022.01.004","article-title":"Compstatins: the dawn of clinical C3-targeted complement inhibition","volume":"43","author":"Lamers","year":"2022","journal-title":"Trends Pharmacol. Sci."},{"key":"B70","doi-asserted-by":"publisher","first-page":"e955","DOI":"10.1016\/S2352-3026(23)00315-0","article-title":"Addition of danicopan to ravulizumab or eculizumab in patients with paroxysmal nocturnal haemoglobinuria and clinically significant extravascular haemolysis (ALPHA): a double-blind, randomised, phase 3 trial","volume":"10","author":"Lee","year":"2023","journal-title":"Lancet Haematol."},{"key":"B71","doi-asserted-by":"publisher","first-page":"100079","DOI":"10.1016\/j.pharmr.2025.100079","article-title":"The complement system: biology, pathology, and therapeutic interventions","volume":"77","author":"Li","year":"2025","journal-title":"Pharmacol. Rev."},{"key":"B72","doi-asserted-by":"publisher","first-page":"60","DOI":"10.1186\/1750-1172-6-60","article-title":"Atypical hemolytic uremic syndrome","volume":"6","author":"Loirat","year":"2011","journal-title":"Orphanet J. Rare Dis."},{"key":"B74","doi-asserted-by":"publisher","first-page":"1503","DOI":"10.1681\/ASN.2014101000","article-title":"Current understanding of the role of complement in IgA nephropathy","volume":"26","author":"Maillard","year":"2015","journal-title":"J. Am. Soc. Nephrol."},{"key":"B75","doi-asserted-by":"publisher","first-page":"1959","DOI":"10.1007\/s00467-025-06673-w","article-title":"Efficacy of complement inhibition with pegcetacoplan in children with C3 glomerulopathy","volume":"40","author":"Mancuso","year":"2025","journal-title":"Pediatr. Nephrol."},{"key":"B76","doi-asserted-by":"publisher","first-page":"1232","DOI":"10.1016\/j.kint.2017.04.017","article-title":"C5 nephritic factors drive the biological phenotype of C3 glomerulopathies","volume":"92","author":"Marinozzi","year":"","journal-title":"Kidney Int."},{"key":"B77","doi-asserted-by":"publisher","first-page":"1603","DOI":"10.1681\/ASN.2016030343","article-title":"Anti-factor B and Anti-C3b autoantibodies in C3 glomerulopathy and Ig-associated membranoproliferative GN","volume":"28","author":"Marinozzi","year":"","journal-title":"J. Am. Soc. Nephrol."},{"key":"B78","doi-asserted-by":"publisher","first-page":"118","DOI":"10.1038\/s41577-023-00926-1","article-title":"A guide to complement biology, pathology and therapeutic opportunity","volume":"24","author":"Mastellos","year":"2024","journal-title":"Nat. Rev. Immunol."},{"key":"B79","doi-asserted-by":"publisher","first-page":"111","DOI":"10.1182\/bloodadvances.2025017540","article-title":"Survival in adults with high-risk TA-TMA: a comparative analysis of narsoplimab vs supportive care","volume":"10","author":"Matsui","year":"2026","journal-title":"Blood Adv."},{"key":"B80","doi-asserted-by":"publisher","first-page":"e230036","DOI":"10.57264\/cer-2023-0036","article-title":"Treatment preference and quality of life impact: ravulizumab vs eculizumab for atypical hemolytic uremic syndrome","volume":"12","author":"Mauch","year":"2023","journal-title":"J. Comp. Eff. Res."},{"key":"B81","doi-asserted-by":"publisher","first-page":"176","DOI":"10.1016\/j.imbio.2011.07.027","article-title":"Off to a slow start: under-development of the complement system in term newborns is more substantial following premature birth","volume":"217","author":"McGreal","year":"2012","journal-title":"Immunobiology"},{"key":"B82","doi-asserted-by":"publisher","first-page":"734","DOI":"10.15585\/mmwr.mm6627e1","article-title":"High risk for invasive meningococcal disease among patients receiving eculizumab (Soliris) despite receipt of meningococcal vaccine","volume":"66","author":"McNamara","year":"2017","journal-title":"MMWR Morb. Mortal. Wkly. Rep."},{"key":"B83","doi-asserted-by":"publisher","first-page":"262","DOI":"10.3389\/fimmu.2015.00262","article-title":"Complement system part I - molecular mechanisms of activation and regulation","volume":"6","author":"Merle","year":"2015","journal-title":"Front. Immunol."},{"key":"B84","doi-asserted-by":"publisher","first-page":"860689","DOI":"10.3389\/fimmu.2022.860689","article-title":"Ex vivo test for measuring complement attack on endothelial cells: from research to bedside","volume":"13","author":"Meuleman","year":"2022","journal-title":"Front. Immunol."},{"key":"B85","doi-asserted-by":"publisher","first-page":"708","DOI":"10.1002\/ana.24770","article-title":"Therapy with eculizumab for patients with CD59 p.Cys89Tyr mutation","volume":"80","author":"Mevorach","year":"2016","journal-title":"Ann. Neurol."},{"key":"B86","doi-asserted-by":"publisher","first-page":"1722","DOI":"10.1016\/S0140-6736(22)01202-8","article-title":"Haemolytic uraemic syndrome","volume":"400","author":"Michael","year":"2022","journal-title":"Lancet."},{"key":"B87","doi-asserted-by":"publisher","first-page":"2539","DOI":"10.3389\/fimmu.2019.02539","article-title":"Current and future approaches for monitoring responses to anti-complement therapeutics","volume":"10","author":"Mohebnasab","year":"2019","journal-title":"Front. Immunol."},{"key":"B88","doi-asserted-by":"publisher","first-page":"135","DOI":"10.1016\/j.therap.2018.02.002","article-title":"Off-label and unlicensed drug use in children population","volume":"73","author":"Moulis","year":"2018","journal-title":"Therapie"},{"key":"B89","doi-asserted-by":"publisher","first-page":"338","DOI":"10.1016\/j.ajt.2023.10.016","article-title":"The banff 2022 kidney meeting report: reappraisal of microvascular inflammation and the role of biopsy-based transcript diagnostics","volume":"24","author":"Naesens","year":"2024","journal-title":"Am. J. Transpl."},{"key":"B90","doi-asserted-by":"publisher","first-page":"113824","DOI":"10.1016\/j.jim.2025.113824","article-title":"Challenges for complement functional assays in the clinical laboratory: from test validation to clinical interpretation","volume":"537","author":"Nandakumar","year":"2025","journal-title":"J. Immunol. Methods."},{"key":"B91","doi-asserted-by":"publisher","first-page":"687","DOI":"10.1159\/000527167","article-title":"Clinical outcomes of patients with C3G or IC-MPGN treated with the factor D inhibitor danicopan: final results from two phase 2 studies","volume":"53","author":"Nester","year":"2022","journal-title":"Am. J. Nephrol."},{"key":"B92","doi-asserted-by":"publisher","first-page":"632","DOI":"10.1056\/NEJMoa1311084","article-title":"Genetic variants in C5 and poor response to eculizumab","volume":"370","author":"Nishimura","year":"2014","journal-title":"N. Engl. J. Med."},{"key":"B93","doi-asserted-by":"publisher","first-page":"1715","DOI":"10.1182\/blood-2014-02-558296","article-title":"Dynamics of complement activation in aHUS and how to monitor eculizumab therapy","volume":"124","author":"Noris","year":"2014","journal-title":"Blood"},{"key":"B94","doi-asserted-by":"publisher","first-page":"2464","DOI":"10.4049\/jimmunol.1701695","article-title":"Statistical validation of rare complement variants provides insights into the molecular basis of atypical hemolytic uremic syndrome and C3 glomerulopathy","volume":"200","author":"Osborne","year":"2018","journal-title":"J. Immunol."},{"key":"B95","doi-asserted-by":"publisher","first-page":"20","DOI":"10.1111\/imr.12715","article-title":"CHAPLE syndrome uncovers the primary role of complement in a familial form of Waldmann's disease","volume":"287","author":"Ozen","year":"2019","journal-title":"Immunol. Rev."},{"key":"B96","doi-asserted-by":"publisher","first-page":"52","DOI":"10.1056\/NEJMoa1615887","article-title":"CD55 deficiency, early-onset protein-losing enteropathy, and thrombosis","volume":"377","author":"Ozen","year":"2017","journal-title":"N. Engl. J. Med."},{"key":"B97","doi-asserted-by":"publisher","first-page":"645","DOI":"10.1016\/S0140-6736(23)02358-9","article-title":"Evaluating the efficacy and safety of pozelimab in patients with CD55 deficiency with hyperactivation of complement, angiopathic thrombosis, and protein-losing enteropathy disease: an open-label phase 2 and 3 study","volume":"403","author":"Ozen","year":"2024","journal-title":"Lancet"},{"key":"B98","doi-asserted-by":"publisher","first-page":"256","DOI":"10.1016\/j.tmrv.2019.09.004","article-title":"Eculizumab and beyond: the past, present, and future of complement therapeutics","volume":"33","author":"Patriquin","year":"2019","journal-title":"Transfus. Med. Rev."},{"key":"B99","doi-asserted-by":"publisher","first-page":"1079","DOI":"10.1038\/ki.2013.377","article-title":"C3 glomerulopathy: consensus report","volume":"84","author":"Pickering","year":"2013","journal-title":"Kidney Int."},{"key":"B100","doi-asserted-by":"publisher","first-page":"614","DOI":"10.1056\/NEJMoa1900866","article-title":"Eculizumab in aquaporin-4-positive neuromyelitis optica spectrum disorder","volume":"381","author":"Pittock","year":"2019","journal-title":"N. Engl. J. Med."},{"key":"B101","doi-asserted-by":"publisher","first-page":"1247","DOI":"10.1016\/j.imbio.2016.06.008","article-title":"Complement analysis 2016: clinical indications, laboratory diagnostics and quality control","volume":"221","author":"Prohaszka","year":"2016","journal-title":"Immunobiology"},{"key":"B102","doi-asserted-by":"publisher","first-page":"1282","DOI":"10.3389\/fimmu.2019.01282","article-title":"Clinical and immunological profile of anti-factor H antibody associated atypical hemolytic uremic syndrome: a nationwide database","volume":"10","author":"Puraswani","year":"2019","journal-title":"Front. Immunol."},{"key":"B103","doi-asserted-by":"publisher","first-page":"991","DOI":"10.1016\/j.mayocp.2018.05.019","article-title":"C3 glomerulopathy: ten years' experience at Mayo clinic","volume":"93","author":"Ravindran","year":"2018","journal-title":"Mayo Clin. Proc."},{"key":"B104","doi-asserted-by":"publisher","first-page":"e2350816","DOI":"10.1002\/eji.202350816","article-title":"Complement-targeted therapeutics: are we there yet, or just getting started?","volume":"54","author":"Ricklin","year":"2024","journal-title":"Eur. J. Immunol."},{"key":"B105","doi-asserted-by":"publisher","first-page":"10","DOI":"10.1016\/j.molimm.2017.05.013","article-title":"Complement in clinical medicine: clinical trials, case reports and therapy monitoring","volume":"89","author":"Ricklin","year":"2017","journal-title":"Mol. Immunol."},{"key":"B106","doi-asserted-by":"publisher","first-page":"1527016","DOI":"10.3389\/fimmu.2024.1527016","article-title":"Novel immunochromatographic test for rapid detection of anti-factor H autoantibodies with an assessment of its clinical relevance","volume":"15","author":"Rodriguez de Cordoba","year":"2024","journal-title":"Front. Immunol."},{"key":"B107","doi-asserted-by":"publisher","first-page":"1351","DOI":"10.1007\/s00467-025-07092-7","article-title":"Pegcetacoplan in idiopathic and familial pediatric C3 glomerulopathy","volume":"41","author":"Roman Ortiz","year":"2026","journal-title":"Pediatr. Nephrol."},{"key":"B108","doi-asserted-by":"publisher","first-page":"1287","DOI":"10.1016\/j.kint.2020.01.035","article-title":"The long-acting C5 inhibitor, Ravulizumab, is effective and safe in adult patients with atypical hemolytic uremic syndrome naive to complement inhibitor treatment","volume":"97","author":"Rondeau","year":"2020","journal-title":"Kidney Int."},{"key":"B109","doi-asserted-by":"publisher","first-page":"1323","DOI":"10.1056\/NEJMoa2027760","article-title":"Sutimlimab in cold agglutinin disease","volume":"384","author":"Roth","year":"2021","journal-title":"N. Engl. J. Med."},{"key":"B110","doi-asserted-by":"publisher","first-page":"980","DOI":"10.1182\/blood.2021014955","article-title":"Sutimlimab in patients with cold agglutinin disease: results of the randomized placebo-controlled phase 3 CADENZA trial","volume":"140","author":"Roth","year":"2022","journal-title":"Blood"},{"key":"B111","doi-asserted-by":"publisher","first-page":"280","DOI":"10.1111\/ejh.13903","article-title":"Sutimlimab provides clinically meaningful improvements in patient-reported outcomes in patients with cold agglutinin disease: results from the randomised, placebo-controlled, phase 3 CADENZA study","volume":"110","author":"Roth","year":"2023","journal-title":"Eur. J. Haematol."},{"key":"B112","doi-asserted-by":"publisher","first-page":"1768","DOI":"10.1002\/ajh.27412","article-title":"Phase 3 randomized COMMODORE 2 trial: crovalimab versus eculizumab in patients with paroxysmal nocturnal hemoglobinuria naive to complement inhibition","volume":"99","author":"Roth","year":"2024","journal-title":"Am. J. Hematol."},{"key":"B113","doi-asserted-by":"publisher","first-page":"1107","DOI":"10.1007\/s00467-013-2711-5","article-title":"Rituximab fails where eculizumab restores renal function in C3nef-related DDD","volume":"29","author":"Rousset-Rouviere","year":"2014","journal-title":"Pediatr. Nephrol."},{"key":"B137","doi-asserted-by":"publisher","first-page":"599","DOI":"10.1056\/NEJMe2608684","article-title":"Retraction: Jayne DRW et al. avacopan for the treatment of ANCAassociated vasculitis","volume":"384","author":"Rubin","year":"2026","journal-title":"N. Engl. J. Med."},{"key":"B114","doi-asserted-by":"publisher","first-page":"641","DOI":"10.1001\/jamadermatol.2022.1156","article-title":"Evaluation of nomacopan for treatment of bullous pemphigoid: a phase 2a nonrandomized controlled trial","volume":"158","author":"Sadik","year":"2022","journal-title":"JAMA Dermatol"},{"key":"B115","doi-asserted-by":"publisher","first-page":"e4330","DOI":"10.1097\/MD.0000000000004330","article-title":"Can eculizumab be discontinued in aHUS? case report and review of the literature","volume":"95","author":"Sahutoglu","year":"2016","journal-title":"Med. Baltim."},{"key":"B116","doi-asserted-by":"publisher","first-page":"11679","DOI":"10.3390\/ijms252111679","article-title":"Beyond recycling antibodies: crovalimab's molecular design enables four-weekly subcutaneous injections for PNH treatment","volume":"25","author":"Sampei","year":"2024","journal-title":"Int. J. Mol. Sci."},{"key":"B117","doi-asserted-by":"publisher","first-page":"75","DOI":"10.1007\/s00467-013-2558-9","article-title":"Long-term remission of atypical HUS with anti-factor H antibodies after cyclophosphamide pulses","volume":"29","author":"Sana","year":"2014","journal-title":"Pediatr. Nephrol."},{"key":"B118","doi-asserted-by":"publisher","first-page":"151","DOI":"10.1016\/j.jtct.2022.11.015","article-title":"Harmonizing definitions for diagnostic criteria and prognostic assessment of transplantation-associated thrombotic microangiopathy: a report on behalf of the european society for blood and marrow transplantation, American society for transplantation and cellular therapy, Asia-Pacific blood and marrow transplantation group, and center for international blood and marrow transplant research","volume":"29","author":"Schoettler","year":"2023","journal-title":"Transpl. Cell Ther."},{"key":"B119","doi-asserted-by":"publisher","first-page":"610","DOI":"10.1016\/j.jtct.2025.05.028","article-title":"An ASTCT, CIBMTR, EBMT, and APBMT consensus statement defining response criteria for hematopoietic cell transplantation associated thrombotic microangiopathy (TA-TMA) directed therapy","volume":"31","author":"Schoettler","year":"","journal-title":"Transpl. Cell Ther."},{"key":"B120","doi-asserted-by":"publisher","first-page":"2040","DOI":"10.1002\/ajh.70044","article-title":"Narsoplimab results in excellent survival in adults and children with hematopoietic cell transplant associated thrombotic microangiopathy (TA-TMA)","volume":"100","author":"Schoettler","year":"","journal-title":"Am. J. Hematol."},{"key":"B121","doi-asserted-by":"publisher","first-page":"2392","DOI":"10.1681\/ASN.2006080811","article-title":"Differential impact of complement mutations on clinical characteristics in atypical hemolytic uremic syndrome","volume":"18","author":"Sellier-Leclerc","year":"2007","journal-title":"J. Am. Soc. Nephrol."},{"key":"B122","doi-asserted-by":"publisher","first-page":"454","DOI":"10.1038\/ki.2012.63","article-title":"Acquired and genetic complement abnormalities play a critical role in dense deposit disease and other C3 glomerulopathies","volume":"82","author":"Servais","year":"2012","journal-title":"Kidney Int."},{"key":"B123","doi-asserted-by":"publisher","first-page":"814","DOI":"10.1007\/s12325-022-02401-0","article-title":"Hereditary angioedema: diagnosis, clinical implications, and pathophysiology","volume":"40","author":"Sinnathamby","year":"2023","journal-title":"Adv. Ther."},{"key":"B124","doi-asserted-by":"publisher","first-page":"227","DOI":"10.1160\/TH08-05-0322","article-title":"Autoantibodies in haemolytic uraemic syndrome (HUS)","volume":"101","author":"Skerka","year":"2009","journal-title":"Thromb. Haemost."},{"key":"B125","doi-asserted-by":"publisher","first-page":"129","DOI":"10.1038\/s41581-018-0107-2","article-title":"C3 glomerulopathy - understanding a rare complement-driven renal disease","volume":"15","author":"Smith","year":"2019","journal-title":"Nat. Rev. Nephrol."},{"key":"B126","doi-asserted-by":"publisher","first-page":"1739","DOI":"10.1007\/s00431-020-03666-9","article-title":"Molecular basis and outcomes of atypical haemolytic uraemic syndrome in Czech children","volume":"179","author":"Stolbova","year":"2020","journal-title":"Eur. J. Pediatr."},{"key":"B127","doi-asserted-by":"publisher","first-page":"36","DOI":"10.1182\/blood.2019000940","article-title":"Secondary myelodysplastic syndrome and leukemia in acquired aplastic anemia and paroxysmal nocturnal hemoglobinuria","volume":"136","author":"Sun","year":"2020","journal-title":"Blood"},{"key":"B128","doi-asserted-by":"publisher","first-page":"586","DOI":"10.1016\/j.semnephrol.2013.08.009","article-title":"Complement-mediated cellular injury","volume":"33","author":"Takano","year":"2013","journal-title":"Semin. Nephrol."},{"key":"B129","doi-asserted-by":"publisher","first-page":"521","DOI":"10.1007\/s00467-021-05088-7","article-title":"A clinical approach to children with C3 glomerulopathy","volume":"37","author":"Vivarelli","year":"2022","journal-title":"Pediatr. Nephrol."},{"key":"B130","doi-asserted-by":"publisher","first-page":"304","DOI":"10.1111\/cei.12890","article-title":"Monitoring of complement activation biomarkers and eculizumab in complement-mediated renal disorders","volume":"187","author":"Wehling","year":"2017","journal-title":"Clin. Exp. Immunol."},{"key":"B131","doi-asserted-by":"publisher","first-page":"392","DOI":"10.1016\/S0140-6736(23)01524-6","article-title":"Complement in human disease: approved and up-and-coming therapeutics","volume":"403","author":"West","year":"2024","journal-title":"Lancet"},{"key":"B132","doi-asserted-by":"publisher","first-page":"447","DOI":"10.1080\/10408363.2021.1907297","article-title":"Complement testing in the clinical laboratory","volume":"58","author":"Willrich","year":"","journal-title":"Crit. Rev. Clin. Lab. Sci."},{"key":"B133","doi-asserted-by":"publisher","first-page":"112944","DOI":"10.1016\/j.jim.2020.112944","article-title":"Monitoring ravulizumab effect on complement assays","volume":"490","author":"Willrich","year":"","journal-title":"J. Immunol. Methods."},{"key":"B134","doi-asserted-by":"publisher","first-page":"6499","DOI":"10.3390\/jcm13216499","article-title":"Changing epidemiology and outcomes of hemolytic uremic syndrome in children: a prospective national cohort study from the Polish pediatric HUS registry and the Polish registry of renal replacement therapy in children","volume":"13","author":"Zagozdzon","year":"2024","journal-title":"J. Clin. Med."},{"key":"B135","doi-asserted-by":"publisher","first-page":"341","DOI":"10.1016\/j.molimm.2019.07.030","article-title":"Compendium of current complement therapeutics","volume":"114","author":"Zelek","year":"2019","journal-title":"Mol. Immunol."},{"key":"B136","doi-asserted-by":"publisher","first-page":"607211","DOI":"10.3389\/fimmu.2020.607211","article-title":"Factor H autoantibodies and complement-mediated diseases","volume":"11","author":"Zhang","year":"2020","journal-title":"Front. Immunol."}],"container-title":["Frontiers in Pharmacology"],"original-title":[],"link":[{"URL":"https:\/\/www.frontiersin.org\/articles\/10.3389\/fphar.2026.1891349\/full","content-type":"unspecified","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2026,9,10]],"date-time":"2026-09-10T08:50:09Z","timestamp":1789030209000},"score":1,"resource":{"primary":{"URL":"https:\/\/www.frontiersin.org\/articles\/10.3389\/fphar.2026.1891349\/full"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2026,9,10]]},"references-count":137,"alternative-id":["10.3389\/fphar.2026.1891349"],"URL":"https:\/\/doi.org\/10.3389\/fphar.2026.1891349","relation":{},"ISSN":["1663-9812"],"issn-type":[{"value":"1663-9812","type":"electronic"}],"subject":[],"published":{"date-parts":[[2026,9,10]]},"article-number":"1891349"}}